Maintenance of Complete Skin Clearance Throughout 3 Years of Continuous Guselkumab Treatment in Patients with Moderate-To-Severe Psoriasis: A Post Hoc Analysis of 5-Year Data from the Voyage 1 Trial
AuthID
P-00V-9HZ
P-00V-9HZ